![]()
©Celoxica 2008. T: +44 (0)1235 863656
Celoxica Holdings plc (AIM: CXA) - a leading provider of FPGA based High Performance Computing solutions, announces the successful implementation of data analysis acceleration in the life sciences environment. Genetic analysis is a fundamental process in modern drug discovery and development but places great demands on data processing. Working with a respected US Life Sciences company, Celoxica was able to accelerate the client's gene sequencing algorithm by a factor of 20, significantly reducing this "bottleneck". The application of Celoxica's technology could have major benefits in the speed and cost of drug development.
This follows the announcement last month of two other successful proof of concept projects in the financial services market.
Lee Staines, Chief Executive of Celoxica commented,
“We
are delighted to announce the completion of another
successful implementation within one of our key industry
verticals. The ever increasing demand for higher performance
coupled with a need for a reduction in power consumption
is driving momentum in our market. We are seeing an
increased level of awareness of our services within
the financial services, life-sciences and oil and
gas industries and believe the potential for our products
to be significant.”
Tel. +44
(0)1235 863 656
Lee Staines, CEO
Michelle Young, CFO
Tel. +44 (0) 20 7651 8688
Tom Moriarty +44 (0) 7843 260 623
Caroline Evans-Jones
Tel. +44 (0) 20 7012 2000
Tom Griffiths
Alasdair Younie
Investor Relations section last updated 8th July 2008